Newsfile Corp
15 Jun 2026, 18:34 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
ADMA Biologics is accused of using 'channel stuffing' to artificially inflate its reported revenue. — Allegations of revenue manipulation via channel stuffing suggest fundamental financial misrepresentation and often lead to severe stock price corrections.
-0.80ADMA Biologics is facing a class action securities lawsuit alleging failure to disclose material information, including undisclosed related party transactions and inadequate internal controls. — Lawsuits alleging corporate fraud and poor internal controls increase legal liabilities and erode investor trust in company governance.
-0.60Which stocks this story touches
The company is mentioned in the context of a securities fraud class action resulting from misrepresentations and a 49% stock decline.
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a class action securities lawsuit alleging fraud, channel stuffing, and lack of internal controls.
The company is noted as having an application deadline for a class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
1h ago
